Phospho-NPM1 (T199) Antibody

What is the role of NPM1 T199 phosphorylation in normal cellular function?

NPM1 (nucleophosmin) is a multifunctional protein involved in diverse cellular processes including ribosome biogenesis, centrosome duplication, protein chaperoning, and DNA damage response. Phosphorylation at threonine 199 (T199) by CDK2-cyclin E is particularly critical for centrosome duplication. Upon phosphorylation at T199, NPM1 dissociates from centrosomes, which is a prerequisite step for centrosomes to initiate duplication . Additionally, T199 phosphorylation is differentially regulated throughout the cell cycle, with particularly high levels observed during mitosis. Immunohistochemical staining reveals cells undergoing mitosis exhibit strong staining for pT199-NPM1 throughout the entire cell .

What are the recommended applications for Phospho-NPM1 (T199) antibodies?

Phospho-NPM1 (T199) antibodies have been validated for several experimental applications:

The antibody shows reliable detection of endogenous levels of NPM1 when phosphorylated at threonine 199, with the target protein typically appearing at approximately 38 kDa on Western blots . These antibodies are specifically designed for research use only and should not be used for diagnostic or therapeutic applications.

How should phospho-NPM1 (T199) antibodies be stored and handled?

For optimal performance and stability:

• Store antibodies at -20°C for long-term storage (up to 1 year from receipt)

• For frequent use and short-term storage, keep at 4°C for up to one month

• Avoid repeated freeze-thaw cycles as this may reduce antibody effectiveness

• Most formulations contain PBS with preservatives (such as 0.05% Proclin300), 50% glycerol, at pH 7.3

How can I validate the specificity of phospho-NPM1 (T199) antibodies in my experimental system?

To properly validate the specificity of phospho-NPM1 (T199) antibodies:

• Phosphatase treatment control: Treat one sample with lambda phosphatase before immunoblotting to confirm the signal is phosphorylation-dependent.

• T199A mutant expression: Express a non-phosphorylatable T199A NPM1 mutant alongside wild-type NPM1 as demonstrated in previous studies. The T199A mutant should not be recognized by the phospho-specific antibody .

• Cell cycle synchronization: Since T199 phosphorylation varies throughout the cell cycle (highest in mitosis), use synchronized cells at different cell cycle stages as positive and negative controls .

• siRNA knockdown: Perform NPM1 knockdown experiments to confirm signal specificity, as demonstrated in studies where NPM1 siRNA transfection resulted in decreased pT199-NPM1 signal .

• Peptide competition assay: Pre-incubate the antibody with the phosphorylated peptide immunogen to block specific binding.

How does ionizing radiation affect NPM1 T199 phosphorylation, and what are the methodological considerations for studying this phenomenon?

Ionizing radiation induces dephosphorylation of NPM1 at T199 in multiple cancer cell lines, with the timing and persistence varying between cell types. This dephosphorylation occurs rapidly (within 1 hour) and is not attributable to cell cycle arrest, which only becomes detectable after 6 hours post-irradiation .

Methodological considerations:

• Fast fractionated lysis protocol: To capture rapid phosphorylation changes, use protocols that quickly separate cellular compartments while preserving phosphorylation status.

• Phosphatase inhibitors: Include phosphatase inhibitors in all buffers and work strictly on ice to prevent artifactual dephosphorylation.

• Radiation dose standardization: Most studies use 8 Gy dose, but optimize based on cell type.

• Time course: Sample collection at multiple time points (1 min, 10 min, 30 min, 1 hr, 2 hr, 6 hr, 24 hr) is essential to capture the complete dephosphorylation and potential re-phosphorylation dynamics .

• Parallel cell cycle analysis: Perform flow cytometry analysis of cell cycle to distinguish phosphorylation changes from cell cycle effects.

Data from a representative study showing NPM1 T199 dephosphorylation after irradiation:

• A549 cells: Complete dephosphorylation persisting for 24 hours

• HNSCCUM-02T cells: Partial dephosphorylation with return to basal levels after 24 hours

• HeLa cells: Complete dephosphorylation after 2 hours with re-phosphorylation by 24 hours

What is the significance of subcellular localization in interpreting phospho-NPM1 (T199) antibody results?

NPM1 is predominantly nucleolar but can redistribute between cellular compartments. The phosphorylation status of NPM1 at different sites, including T199, influences this localization pattern. Research shows that:

• pT199-NPM1 is more prominent in the cytoplasm than in the nucleus in multiple cell lines

• This differential localization must be considered when interpreting results from fractionated samples

• pT199-NPM1 localization in the cytoplasm aligns with studies showing that this phosphorylation reduces NPM1's binding to nucleic acids and thus its affinity for the nucleus

For accurate analysis:

• Use proper cell fractionation techniques that preserve phosphorylation status

• Include compartment-specific markers (e.g., GAPDH for cytoplasm, histone H3 for nucleus) to verify fractionation quality

• Normalize phosphorylation levels to total NPM1 within each compartment separately

• Consider that single-site mutations may not disrupt localization, as multiple phosphorylation sites likely work cooperatively

How do I reconcile contradictory findings about NPM1 T199 phosphorylation in DNA damage response?

The literature presents some seemingly contradictory findings regarding NPM1 T199 phosphorylation in DNA damage response:

• Koike et al. showed phosphorylated T199 NPM1 (pT199-NPM1) is recruited to DNA damage foci after ionizing radiation, suggesting a role in DNA repair .

• Deutzmann et al. observed dephosphorylation of T199 within an hour after irradiation in multiple cell lines .

To reconcile these findings:

• Consider temporal dynamics: Initial recruitment of existing pT199-NPM1 to damage sites may occur, followed by subsequent dephosphorylation as part of the ongoing repair process.

• Examine cell-type specificity: Different cell types show varying patterns of phosphorylation/dephosphorylation (e.g., A549 vs. HeLa cells show different recovery timing).

• Account for compartmentalization: These phosphorylation events may occur in different subcellular compartments.

• Validate with multiple approaches: Use both immunofluorescence (for localization) and Western blotting (for total levels) to get a complete picture of phosphorylation dynamics.

What cell-type specific differences should be considered when analyzing phospho-NPM1 (T199) results?

Research demonstrates significant cell-type variability in NPM1 T199 phosphorylation patterns:

• Expression levels: NPM1 expression varies across cell lines (highest in HeLa, followed by HNSCCUM-02T and A549) , which affects baseline phosphorylation.

• p53 status: Cells with different p53 status (wild-type vs. mutant) show varying patterns of NPM1 phosphorylation regulation. A549 and HeLa (wild-type p53) show different dephosphorylation kinetics compared to HNSCCUM-02T (mutant p53) .

• Response to irradiation: The duration and extent of T199 dephosphorylation after irradiation varies:

  • A549: Complete dephosphorylation persisting 24 hours

  • HNSCCUM-02T: Partial dephosphorylation with recovery at 24 hours

  • HeLa: Complete dephosphorylation with recovery at 24 hours

• Cancer vs. normal cells: Cancer-specific mutations like NPMc (cytoplasmic NPM1 mutation) show elevated T199 phosphorylation compared to cells with wild-type NPM1 .

When planning experiments, include multiple cell lines and interpret results within the context of their genetic background, particularly p53 status and NPM1 mutation status.

What is the relationship between NPM1 T199 phosphorylation and radiosensitivity in cancer cells?

NPM1 T199 phosphorylation status has been linked to radiosensitivity of cancer cells:

• YTR107 small molecule: Targeting NPM1 with the small molecule YTR107 prevents pT199-NPM1 foci formation at DNA damage sites, resulting in radiosensitization of cancer cells .

• Knockdown effects: Knockdown of NPM1 significantly reduces tumor cell survival after irradiation in colony formation assays .

• Phosphorylation dynamics: Rapid dephosphorylation of NPM1 at T199 after irradiation appears to be part of the immediate response to radiation damage, and is potentially important for tumor cell survival .

• NPM1 mutants: Expression of the non-phosphorylatable T199A NPM1 mutant leads to prolonged persistence of radiation-induced RAD51 foci and unrepaired DNA damage .

These findings suggest targeting NPM1 phosphorylation could be a rational strategy for enhancing radiotherapy effectiveness in cancer treatment. Colony formation assays show that cells with disrupted NPM1 phosphorylation have reduced survival following radiation exposure compared to control cells .

How can phospho-NPM1 (T199) antibodies be used to study the mechanisms of DNA double-strand break repair?

Phospho-NPM1 (T199) antibodies provide valuable tools for investigating DNA double-strand break (DSB) repair mechanisms:

• Co-localization studies: Use phospho-NPM1 (T199) antibodies alongside γH2AX and RAD51 antibodies in immunofluorescence to visualize recruitment of pT199-NPM1 to DSB sites. Research has shown that pT199-NPM1 co-localizes with γH2AX foci (yellow foci denoted by white arrows in microscopy) .

• Sequential recruitment analysis: Track the temporal order of repair factor recruitment by fixing cells at different time points after irradiation.

• RNF8/RNF168 dependency: Studies show that pT199-NPM1 recruitment to DSBs is dependent on the E3 ubiquitin ligases RNF8 and RNF168, suggesting it functions downstream of the initial ubiquitination events in DSB repair .

• Mutant complementation assays: In NPM1-null cells, compare the ability of wild-type NPM1 versus T199A mutant to restore normal DSB repair capacity. Research demonstrates that the T199A mutant fails to reduce γH2AX foci compared to wild-type NPM1 .

• BRCA1/RAP80 interaction: Depletion of BRCA1 or RAP80 enhances and prolongs radiation-induced NPM1 foci, suggesting these proteins regulate pT199-NPM1 dynamics at DSB sites .

These methodologies can reveal how pT199-NPM1 contributes to the choice between homologous recombination and non-homologous end joining repair pathways.

Can phospho-NPM1 (T199) levels serve as biomarkers for predicting radiotherapy response in cancer?

Several lines of evidence suggest phospho-NPM1 (T199) levels may have potential as predictive biomarkers for radiotherapy response:

• Tissue microarray analysis: Immunohistochemical staining of a non-small cell lung cancer (NSCLC) tissue microarray demonstrated variable NPM1 expression across tumor samples, with certain subtypes showing significantly higher NPM1 levels .

• Correlation with radiosensitivity: Cancer cell lines with different baseline pT199-NPM1 levels show varying responses to radiation. Modulation of pT199-NPM1 levels alters radiosensitivity in laboratory models .

• NPM1 overexpression in tumors: The Oncomine database confirms NPM1 overexpression in subsets of human NSCLC, suggesting potential clinical relevance .

• Standardization of detection: Establish standardized immunohistochemical scoring for pT199-NPM1 (e.g., using a 1-3 scale for cytoplasmic staining intensity).

• Dynamic vs. static measurement: Determine whether baseline levels or post-radiation changes in pT199-NPM1 are more predictive of response.

• Multivariate analysis: Assess whether pT199-NPM1 adds independent predictive value when combined with established factors like p53 status.

• Prospective validation: Design prospective clinical studies to correlate pre-treatment and post-treatment pT199-NPM1 levels with radiotherapy outcomes.

Current evidence suggests this marker has research potential, but requires further validation in larger clinical cohorts with standardized methodologies.

What methodological approaches can distinguish between the different phosphorylation sites on NPM1?

NPM1 contains multiple phosphorylation sites including Ser4, Ser125, Thr199, Thr234/237, which can be challenging to distinguish. Research-grade approaches include:

• Phospho-specific antibodies: Use highly specific antibodies that recognize individual phosphorylation sites. Validation data should demonstrate no cross-reactivity with other phosphorylation sites .

• Phosphorylation site mutants: Generate expression constructs with single or multiple phosphorylation sites mutated to non-phosphorylatable residues (e.g., T199A) to confirm antibody specificity .

• Mass spectrometry:

  • Phosphopeptide enrichment followed by LC-MS/MS

  • Use both collision-induced dissociation (CID) and electron transfer dissociation (ETD) fragmentation for comprehensive coverage

  • Quantify relative abundance of different phosphorylation sites

• 2D gel electrophoresis: Separate phosphorylated species based on charge differences introduced by phosphorylation.

• Site-specific dephosphorylation: Treat samples with phosphatases that show preference for certain motifs.

• Phospho-proteomic profiling: Comparative analysis of phosphoproteome before and after specific stimuli (e.g., irradiation) has successfully identified NPM1 phosphorylation dynamics at different sites .